Predictors of all-cause and cardiovascular-specific mortality in type 2 diabetes: A competing risk modeling of an Iranian population

Sadeghpour, Sahar; Faghihimani, Elham; Hassanzadeh, Akbar; Amini, Masoud; Mansourian, Marjan

Predictors of all-cause and cardiovascular-specific mortality in type 2 diabetes: A competing risk modeling of an Iranian population

Authors

¹ Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran

² Endocrinology and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: In Asian population, diabetes mellitus is increasing and has become an important health problem in recent decades. In Iran, cardiovascular disease (CVD) accounts for nearly 46% of the total costs spent for diabetes-associated diseases. Because individuals with diabetes have highly increased CVD risk compared with normal individuals, it is important to diagnosis factors that may increase CVD risk in diabetic patients. The study objective was to identify predictors associated with CVD mortality in patients with type 2 diabetes (T2D) and to develop a prediction model for cardiovascular (CV)-death using a competing risk approach.
Materials and Methods: The study population consisted of 2638 T2D (male = 1110, female = 1528) patients aged ≥35 years attending from Endocrine and Metabolism Research Center in Isfahan for a mean follow-up period of 12 years; predictors for different cause of death were evaluated using cause specific Cox proportional and subdistribution hazards models.

Results: Based on competing modeling, the increase in blood pressure (BP) (spontaneously hypertensive rats [SHR]: 1.64), cholesterol (SHR: 1.55), and duration of diabetes (SHR: 2.03) were associated with CVD-death. Also, the increase in BP (SHR: 1.85), fasting blood sugar (SHR: 2.94), and duration of diabetes (SHR: 1.68) were associated with other death (consist of cerebrovascular accidents, cancer, infection, and diabetic nephropathy).
Conclusions: This finding suggests that more attention should be paid to the management of CV risk in type 2 diabetic patients with high cholesterol, high BP, and long diabetes duration.

Keywords

References

1.	Lotfi MH, Saadati H, Afzali M. Prevalence of diabetes in people aged ≥30 years: The results of screen-ing program of Yazd Province, Iran, in 2012. J Res Health Sci 2014;14:87-91.
2.	Anjana RM, Ali MK, Pradeepa R, Deepa M, Datta M, Unnikrishnan R, et al. The need for obtaining accurate nationwide estimates of diabetes prevalence in India-rationale for a national study on diabetes. Indian J Med Res 2011;133:369-80. [PUBMED]
3.	Ren X, Zhang X, Zhang X, Gu W, Chen K, Le Y, et al. Type 2 diabetes mellitus associated with increased risk for colorectal cancer: Evidence from an international ecological study and population-based risk analysis in China. Public Health 2009;123:540-4.
4.	Javanbakht M, Abolhasani F, Mashayekhi A, Baradaran HR, Jahangiri Noudeh Y. Health related quality of life in patients with type 2 diabetes mellitus in Iran: A national survey. PLoS One 2012;7:e44526.
5.	Rahmanian K, Shojaei M, Jahromi AS. Relation of type 2 diabetes mellitus with gender, education, and marital status in an Iranian urban population. Rep Biochem Mol Biol 2013;1:1-5.
6.	Kiadaliri A, Najafi B. Obesity in type 2 diabetes mellitus: A review of health economics' evidences. Int J Healthc Insur Equity 2013;1:1-8.
7.	Vinagre I, Mata-Cases M, Hermosilla E, Morros R, Fina F, Rosell M, et al. Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain). Diabetes Care 2012;35:774-9.
8.	Rawal LB, Tapp RJ, Williams ED, Chan C, Yasin S, Oldenburg B. Prevention of type 2 diabetes and its complications in developing countries: A review. Int J Behav Med 2012;19:121-33.
9.	Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes 2014;5:444-70.
10.	Gomes MD. Impact of diabetes on cardiovascular disease: An update. Int J Hypertens 2013;2013:1-15.
11.	Tan M, Wong T, Chan Y, Joseph A, Hejar A, Ng O. Predictors of cardiovascular disease in patients with type 2 diabetes mellitus. Int J Collab Res Intern Med Public Health 2013;5:492-506.
12.	Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013;34:3035-87.
13.	Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: The strong heart study. Diabetes Care 2003;26:16-23.
14.	Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ 1998;316:823-8.
15.	Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008;359:1565-76.
16.	Spijkerman AM, Dekker JM, Nijpels G, Jager A, Kostense PJ, van Hinsbergh VW, et al. Impact of diabetes duration and cardiovascular risk factors on mortality in type 2 diabetes: The Hoorn Study. Eur J Clin Invest 2002;32:924-30.
17.	Chen AH, Tseng CH. The role of triglyceride in cardiovascular disease in asian patients with type 2 diabetes – A systematic review. Rev Diabet Stud 2013;10:101-9.
18.	Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep 2011;13:544-52.
19.	Khalangot M, Tronko M, Kravchenko V, Kulchinska J, Hu G. Body mass index and the risk of total and cardiovascular mortality among patients with type 2 diabetes: A large prospective study in Ukraine. Heart 2009;95:454-60.
20.	Alwan A. Global Status Report on Noncommunicable Diseases 2010. Geneva: World Health Organization; 2011.
21.	Tan K. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-63.
22.	Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
23.	Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-219.
24.	Health UDo, Services H, Control CfD, Prevention. Diabetes Report Card; 2012. Atlanta, GA. 2012.
25.	Roth GA, Fihn SD, Mokdad AH, Aekplakorn W, Hasegawa T, Lim SS. High total serum cholesterol, medication coverage and therapeutic control: An analysis of national health examination survey data from eight countries. Bull World Health Organ 2011;89:92-101.
26.	American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014;37 Suppl 1:S14-80.
27.	Koller MT, Raatz H, Steyerberg EW, Wolbers M. Competing risks and the clinical community: Irrelevance or ignorance? Stat Med 2012;31:1089-97.
28.	Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: Competing risks and multi-state models. Stat Med 2007;26:2389-430.
29.	Andersen PK, Geskus RB, de Witte T, Putter H. Competing risks in epidemiology: Possibilities and pitfalls. Int J Epidemiol 2012;41:861-70.
30.	Pintilie M. Competing Risks: A Practical Perspective. Canada: John Wiley and Sons; 2006.
31.	Terry M, Therneau TL. Survival Analysis. Package R; 2014. Available from: http://cran.r-project.org/web/packages/survival/survival.pdf. [Last accessed on 2015 Feb].
32.	Gray B. Cmprsk: Subdistribution Analysis of Competing Risks. R Package; 2014. Available from: http://cran.r-project.org/web/packages/cmprsk/cmprsk.pdf. [Last accessed on 2015 Feb].
33.	Pintilie M. Dealing with competing risks: Testing covariates and calculating sample size. Stat Med 2002;21:3317-24.
34.	Latouche A, Porcher R. Sample size calculations in the presence of competing risks. Stat Med 2007;26:5370-80.
35.	Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 2001;161:1717-23.
36.	Morgan CL, Currie CJ, Stott NC, Smithers M, Butler CC, Peters JR. The prevalence of multiple diabetes-related complications. Diabet Med 2000;17:146-51.
37.	Jarrett RJ, Shipley MJ. Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease – Putative association via common antecedents; further evidence from the Whitehall Study. Diabetologia 1988;31:737-40.
38.	Haffner SM, Mitchell BD, Stern MP, Hazuda HP. Macrovascular complications in Mexican Americans with type II diabetes. Diabetes Care 1991;14:665-71.
39.	Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: Influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med 2011;171:404-10.
40.	Brun E, Nelson RG, Bennett PH, Imperatore G, Zoppini G, Verlato G, et al. Diabetes duration and cause-specific mortality in the Verona Diabetes Study. Diabetes Care 2000;23:1119-23.
41.	Cho E, Rimm EB, Stampfer MJ, Willett WC, Hu FB. The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol 2002;40:954-60.
42.	Chen G, McAlister FA, Walker RL, Hemmelgarn BR, Campbell NR. Cardiovascular outcomes in framingham participants with diabetes: The importance of blood pressure. Hypertension 2011;57:891-7.
43.	Lu WQ, Resnick HE, Jablonski KA, Jain AK, Jones KL, Robbins DC, et al. Effects of glycaemic control on cardiovascular disease in diabetic American Indians: The Strong Heart Study. Diabet Med 2004;21:311-7.
44.	Hsieh YT, Tu ST, Cho TJ, Chang SJ, Chen JF, Hsieh MC. Visit-to-visit variability in blood pressure strongly predicts all-cause mortality in patients with type 2 diabetes: A 5·5-year prospective analysis. Eur J Clin Invest 2012;42:245-53.
45.	Boulanger JM, Hill MD; CHEP (Canadian Hypertension Educational Program). Hypertension and stroke: 2005 Canadian Hypertension Educational Program recommendations. Can J Neurol Sci 2005;32:403-8.
46.	Berry C, Tardif JC, Bourassa MG. Coronary heart disease in patients with diabetes: Part I: Recent advances in prevention and noninvasive management. J Am Coll Cardiol 2007;49:631-42.
47.	Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13.
48.	Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998;317:713-20.
49.	Bonakdaran S, Ebrahimzadeh S, Noghabi SH. Cardiovascular disease and risk factors in patients with type 2 diabetes mellitus in Mashhad, Islamic Republic of Iran. East Mediterr Health J 2011;17:640-6.
50.	Imperatore G, Cadwell BL, Geiss L, Saadinne JB, Williams DE, Ford ES, et al. Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination Surveys, 1971-2000. Am J Epidemiol 2004;160:531-9.
51.	Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
52.	LaRosa JC. Understanding risk in hypercholesterolemia. Clin Cardiol 2003;26 1 Suppl 1:I3-6.
53.	Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med 1990;322:1635-41.
54.	Jousilahti P, Vartiainen E, Pekkanen J, Tuomilehto J, Sundvall J, Puska P. Serum cholesterol distribution and coronary heart disease risk: Observations and predictions among middle-aged population in eastern Finland. Circulation 1998;97:1087-94.
55.	Szklo M, Chambless LE, Folsom AR, Gotto A Jr, Nieto FJ, Patsch W, et al. Trends in plasma cholesterol levels in the atherosclerosis risk in communities (ARIC) study. Prev Med 2000;30:252-9.
56.	Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ; Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-60.
57.	Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang KY, et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med 1993;328:313-8.

Advanced Biomedical Research